HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
KRYS
Krystal Biotech, Inc.
KRYS's fundamentals are strong: revenue grew 26% and its operating margin rose 6 points to 48%. At 42x earnings, it's trading in line with its usual 44x. Analysts expect that strong growth to continue.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
KRYS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
KRYS's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
KRYS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 35x | $261 | -15% |
| Forward | 35x | $306 | — |
| Current | 42x | $306 | — |
| Fair | 44x | $321 | +5.1% |
| Expensive | 79x | $579 | +89% |
Historical ranges are pointers, not guarantees.
KRYS's PE is in its fair range at 42x. If earnings grow as analysts expect, today's price would be 35x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
KRYS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
KRYS has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
KRYS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.68 | +18% |
| Q3 2026 | $7.36 | +10% |
| Q2 2026 | $7.97 | +62% |
| Q1 2026 | $7.47 | +79% |
| Q4 2025 | $6.84 | +128% |
| Q3 2025 | $6.68 | +221% |
| Q2 2025 | $4.93 | +24% |
| Q1 2025 | $4.17 | +91% |
| Q4 2024 | $3.00 | +669% |
KRYS has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over KRYS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
KRYS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $127.3M | +30% |
| Q2 2026 | $119.2M | +24% |
| Q1 2026 | $116.4M | +32% |
| Q4 2025 | $107.1M | +18% |
| Q3 2025 | $97.8M | +17% |
| Q2 2025 | $96M | +37% |
| Q1 2025 | $88.2M | +95% |
| Q4 2024 | $91.1M | +116% |
KRYS's revenue has grown year over year every quarter since late 2024: $127M last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 56% | +14 points |
| Q2 2026 | 49% | +8.1 points |
| Q1 2026 | 46% | +5.1 points |
| Q4 2025 | 41% | -4.1 points |
| Q3 2025 | 42% | +16 points |
| Q2 2025 | 41% | +29 points |
| Q1 2025 | 41% | +56 points |
| Q4 2024 | 45% | +38 points |
KRYS has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
KRYS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $90.3M | +138% |
| Q2 2026 | $71.2M | +40% |
| Q1 2026 | $73.2M | +196% |
| Q4 2025 | $75.4M | +45% |
| Q3 2025 | $38M | -34% |
| Q2 2025 | $50.8M | +$56.1M |
| Q1 2025 | $24.8M | +69% |
| Q4 2024 | $52M | +$61.1M |
KRYS has burned cash in most quarters: $310M over the past year, up 87% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over KRYS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
KRYS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +181K shares |
| 1 year | +3.4% | +1M shares |
| 3 years | +6.7% | +1.9M shares |
| 5 years | +39% | +8.6M shares |
| Available history | +94% | +14.9M shares |
KRYS has 31M diluted shares, up 3.4% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
KRYS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.0x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.7x | Net Cash |
| Q4 2025 | -3.0x | Net Cash |
| Q3 2025 | -2.4x | Net Cash |
| Q2 2025 | -2.5x | Net Cash |
| Q1 2025 | -2.7x | Net Cash |
| Q4 2024 | -4.8x | Net Cash |
KRYS has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
KRYS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.9 | Neutral |
| Stochastic | 31.3 | Neutral |
KRYS's weekly RSI is 46 (neutral) and its Stochastic is 31 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
KRYS PE vs Healthcare Sector
| Metric | KRYS | Sector median | Relative |
|---|---|---|---|
| PE | 42x | 26x | 61% above |
| PE % | 42 | 29 | 13 pts above |
KRYS is trading at 42x earnings, a 61% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
KRYS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $320.8 | 4.7% below |
| 20 week MA | $336.9 | 9.3% below |
| 50 week MA | $300.8 | 1.6% above |
| 100 week MA | $231.7 | 32% above |
| 200 week MA | $184.5 | 66% above |
KRYS has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
KRYS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $60.2 | $60.6 | +0.7% |
| 2021 | $60.6 | $72.3 | +19% |
| 2022 | $72.3 | $76.6 | +5.9% |
| 2023 | $76.6 | $124.1 | +62% |
| 2024 | $124.1 | $159.3 | +28% |
| 2025 | $159.3 | $252.2 | +58% |
| 2026 YTD | $252.2 | $305.7 | +21% |
KRYS has the edge over HIMS on returns for 2026, with the stronger performance.